Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gary Buck

Pain Medicine Vineland, NJ Medical Doctor

NPI 1427054253 CMS profile 291820

510 E Landis Ave, Vineland, NJ 08360

Open in the dashboard

General payments

$2,242

133 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gary Buck of Vineland, NJ is reported in the CMS Open Payments database as having received $2,242 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $379 1
2023 General $36 2
2022 General $79 4
2021 General $239 17
2020 General $191 15
2019 General $1,318 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Buck
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Gary Buck were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Gary Buck Pain Medicine median Middle half National median
2019 $1,318 $498 $126–$1,682 $163
2020 $191 $284 $80–$910 $114
2021 $239 $399 $112–$1,219 $132
2022 $79 $455 $137–$1,484 $149
2023 $36 $484 $128–$1,495 $160
2024 $379 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Vertex Pharmaceuticals Incorporated $379 1 payment
  2. Abbott Laboratories $340 16 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $186 16 payments
  4. US WorldMeds, LLC $182 16 payments
  5. Daiichi Sankyo Inc. $171 17 payments
  6. Biodelivery Sciences International, Inc. $161 15 payments
  7. Medtronic USA, Inc. $111 1 payment
  8. Boston Scientific Corporation $102 6 payments
  9. Collegium Pharmaceutical, Inc. $86 6 payments
  10. Nevro Corp. $71 4 payments
  11. Other $454 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,863 132 payments
  2. Consulting Fee $379 1 payment
Products named General payments · program years 2019–2024
  1. Proclaim Family of SCS IPGs $258 10 payments
  2. Lucemyra/Lofexidine $182 16 payments
  3. Morphabond ER $171 17 payments
  4. LUCEMYRA $121 10 payments
  5. INTELLIS $111 1 payment
  6. BUNAVAIL 4.2 mg single pouch $106 11 payments
  7. BUNAVAIL 6.3 mg 30-count box $106 11 payments
  8. BUNAVAIL 2.1 mg single pouch $106 11 payments
  9. BUNAVAIL 4.2 mg 30-count box $106 11 payments
  10. BUNAVAIL 2.1 mg 30-count box $106 11 payments
  11. Other $1,081 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$108,007

Medicare's payments for the services billed

Medicare patients

775

Average age 76

Services billed

972

448 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 40%
Ischemic heart disease 28%
Chronic kidney disease 17%
Osteoporosis 16%
Cancer 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record